Frank P. Bymaster
Lilly Neuroscience Research
Lilly Research Laboratories
Lilly Corporate Center
Indianapolis
USA
Name/email consistency: high
- New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Bymaster, F.P., McNamara, R.K., Tran, P.V. Expert. Opin. Investig. Drugs (2003)
- Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Bymaster, F.P., McKinzie, D.L., Felder, C.C., Wess, J. Neurochem. Res. (2003)
- Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Bymaster, F.P., Carter, P.A., Yamada, M., Gomeza, J., Wess, J., Hamilton, S.E., Nathanson, N.M., McKinzie, D.L., Felder, C.C. Eur. J. Neurosci. (2003)
- Muscarinic mechanisms of antipsychotic atypicality. Bymaster, F.P., Felder, C.C., Tzavara, E., Nomikos, G.G., Calligaro, D.O., Mckinzie, D.L. Prog. Neuropsychopharmacol. Biol. Psychiatry (2003)
- Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Bymaster, F.P., Zhang, W., Carter, P.A., Shaw, J., Chernet, E., Phebus, L., Wong, D.T., Perry, K.W. Psychopharmacology (Berl.) (2002)
- Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Bymaster, F.P., Felder, C.C. Mol. Psychiatry (2002)
- Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Bymaster, F.P., Katner, J.S., Nelson, D.L., Hemrick-Luecke, S.K., Threlkeld, P.G., Heiligenstein, J.H., Morin, S.M., Gehlert, D.R., Perry, K.W. Neuropsychopharmacology (2002)
- Muscarinic receptors as a target for drugs treating schizophrenia. Bymaster, F.P., Felder, C., Ahmed, S., McKinzie, D. Curr. Drug. Targets. CNS. Neurol. Disord (2002)
- Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice. Bymaster, F.P., Carter, P.A., Zhang, L., Falcone, J.F., Stengel, P.W., Cohen, M.L., Shannon, H.E., Gomeza, J., Wess, J., Felder, C.C. Life Sci. (2001)
- Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus in vivo. Bymaster, F.P., Carter, P.A., DeLapp, N.W., Calligaro, D.O., Felder, C.C. Brain Res. (2001)
- Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Bymaster, F.P., Falcone, J.F., Bauzon, D., Kennedy, J.S., Schenck, K., DeLapp, N.W., Cohen, M.L. Eur. J. Pharmacol. (2001)
- Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Bymaster, F.P., Falcone, J.F. Eur. J. Pharmacol. (2000)
- Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Bymaster, F.P., Nelson, D.L., DeLapp, N.W., Falcone, J.F., Eckols, K., Truex, L.L., Foreman, M.M., Lucaites, V.L., Calligaro, D.O. Schizophr. Res. (1999)
- Arachidonic acid release in cell lines transfected with muscarinic receptors: a simple functional assay to determine response of agonists. Bymaster, F.P., Calligaro, D.O., Falcone, J.F. Cell. Signal. (1999)
- Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Bymaster, F.P., Carter, P.A., Peters, S.C., Zhang, W., Ward, J.S., Mitch, C.H., Calligaro, D.O., Whitesitt, C.A., DeLapp, N., Shannon, H.E., Rimvall, K., Jeppesen, L., Sheardown, M.J., Fink-Jensen, A., Sauerberg, P. Brain Res. (1998)
